2024
Short versus 1-Year Dual Antiplatelet Therapy after Percutaneous Coronary Intervention: An Updated Systematic Review and Meta-Analysis
Joseph M, Krishna M, Ezenna C, Pereira V, Ismayl M, Nanna M, Bangalore S, Goldsweig A. Short versus 1-Year Dual Antiplatelet Therapy after Percutaneous Coronary Intervention: An Updated Systematic Review and Meta-Analysis. The American Journal Of Cardiology 2024 PMID: 39577682, DOI: 10.1016/j.amjcard.2024.10.038.Peer-Reviewed Original ResearchPost-percutaneous coronary interventionAcute coronary syndromeDrug-eluting stentsPercutaneous coronary interventionCoronary interventionAcute coronary syndrome cohortCochrane Central databasesShortening DAPT durationMonths post-percutaneous coronary interventionClopidogrel subgroupRandomized controlled trialsNo significant differenceCoronary syndromeMonotherapyTicagrelor monotherapyDAPT durationShorter DAPTBleedingStent thrombosisP2Y12iMyocardial infarctionControlled trialsSubgroup interactionsDAPTMeta-analysisInvasive Versus Conservative Strategy in Older Adults ≥75 Years of Age With Non-ST-segment-Elevation Acute Coronary Syndrome: A Systematic Review and Meta-Analysis of Randomized Controlled Trials.
Rout A, Moumneh M, Kalra K, Singh S, Garg A, Kunadian V, Biscaglia S, Alkhouli M, Rymer J, Batchelor W, Nanna M, Damluji A. Invasive Versus Conservative Strategy in Older Adults ≥75 Years of Age With Non-ST-segment-Elevation Acute Coronary Syndrome: A Systematic Review and Meta-Analysis of Randomized Controlled Trials. Journal Of The American Heart Association 2024, 13: e036151. PMID: 39494560, DOI: 10.1161/jaha.124.036151.Peer-Reviewed Original ResearchConceptsNon-ST segment elevation acute coronary syndromeAcute coronary syndromeComposite of deathBurden of geriatric conditionsRandomized controlled trialsCoronary syndromeMyocardial infarctionYears of ageInvasive strategyOlder adultsControlled trialsGeriatric conditionsOlder patientsCardiovascular deathOdds ratioMeta-analysis of randomized controlled trialsNon-ST segment elevationSecondary end pointsMeta-analysisFixed effects meta-analysisAll-cause deathEffects meta-analysisYounger patientsFollow-upDecreased riskMachine learning prediction of one-year mortality after percutaneous coronary intervention in acute coronary syndrome patients
Hosseini K, Behnoush A, Khalaji A, Etemadi A, Soleimani H, Pasebani Y, Jenab Y, Masoudkabir F, Tajdini M, Mehrani M, Nanna M. Machine learning prediction of one-year mortality after percutaneous coronary intervention in acute coronary syndrome patients. International Journal Of Cardiology 2024, 409: 132191. PMID: 38777044, DOI: 10.1016/j.ijcard.2024.132191.Peer-Reviewed Original ResearchConceptsPercutaneous coronary interventionLogistic regressionPost-PCI mortalityPrediction of one-year mortalityCoronary interventionPrediction of 1-year mortalityBody mass indexAcute coronary syndrome patientsOne-year mortalityIndividual-level assessmentsReceiver operating characteristic curveAcute coronary syndromeCoronary syndrome patientsTehran Heart CenterRates of comorbiditiesMass indexHigher ageSyndrome patientsCoronary syndromeHeart CenterFollow-upLipid profileU-shaped correlationPatientsCharacteristic curveDuration of Dual Antiplatelet Therapy After Percutaneous Coronary Intervention in Patients With Type 2 Diabetes Mellitus: A Systematic Review and Network Meta-analysis
Park D, Hu J, Campbell G, Goldwag K, Kelsey M, Altin S, Gallegos-Kattán C, Nanna M. Duration of Dual Antiplatelet Therapy After Percutaneous Coronary Intervention in Patients With Type 2 Diabetes Mellitus: A Systematic Review and Network Meta-analysis. Journal Of The Society For Cardiovascular Angiography & Interventions 2024, 3: 101859. PMID: 39131993, PMCID: PMC11307649, DOI: 10.1016/j.jscai.2024.101859.Peer-Reviewed Original ResearchMonths of DAPTDuration of dual antiplatelet therapyNet adverse clinical eventsType 2 diabetes mellitusDual antiplatelet therapyAcute coronary syndromeRandomized controlled trialsSensitivity analysis of trialsPercutaneous coronary interventionCoronary interventionNo significant differenceAntiplatelet therapyAnalysis of trialsCoronary syndromeControlled trialsMeta-analysis of patientsStent thrombosisMeta-analysisDAPT durationClinicians greater flexibilityStudy-level meta-analysisOptimal duration of dual antiplatelet therapyHigher risk of adverse eventsPostpercutaneous coronary interventionRisk of adverse events
2022
TCT-9 Invasive Strategy Versus Medical Therapy in Older Adults ≥75 Years of Age With Non–ST-Segment Elevation Acute Coronary Syndrome: A Systematic Review and Meta-analysis
Rout A, Garg A, Lohana V, Singh V, Rymer J, Nanna M, Kochar A, Damluji A. TCT-9 Invasive Strategy Versus Medical Therapy in Older Adults ≥75 Years of Age With Non–ST-Segment Elevation Acute Coronary Syndrome: A Systematic Review and Meta-analysis. Journal Of The American College Of Cardiology 2022, 80: b4. DOI: 10.1016/j.jacc.2022.08.017.Peer-Reviewed Original ResearchShortening the duration of dual antiplatelet therapy after percutaneous coronary intervention for acute coronary syndrome: A systematic review and meta-analysis
Park DY, Wang P, An S, Grimshaw AA, Frampton J, Ohman EM, Rao SV, Nanna MG. Shortening the duration of dual antiplatelet therapy after percutaneous coronary intervention for acute coronary syndrome: A systematic review and meta-analysis. American Heart Journal 2022, 251: 101-114. PMID: 35654162, PMCID: PMC10904033, DOI: 10.1016/j.ahj.2022.05.019.Peer-Reviewed Original ResearchConceptsMonths of DAPTHazard ratioIschemic eventsDuration of DAPTSelect patient characteristicsDual antiplatelet therapyAcute coronary syndromeCoronary artery lesionsPercutaneous coronary interventionConfidence intervalsAssociation of outcomesRandom-effects modelComprehensive literature searchMeta-regression analysisMajor bleedingAntiplatelet therapyCoronary syndromeArtery lesionsCoronary interventionControlled TrialsPatient characteristicsPrespecified outcomesGreater proportionSimilar efficacySystematic review
2020
In ACS, ticagrelor and prasugrel each reduce some ischemic events but increase major bleeding vs. clopidogrel.
Nanna MG, Granger CB. In ACS, ticagrelor and prasugrel each reduce some ischemic events but increase major bleeding vs. clopidogrel. Annals Of Internal Medicine 2020, 173: jc44. PMID: 33075264, DOI: 10.7326/acpj202010200-044.Peer-Reviewed Original ResearchConceptsAcute coronary syndromeMajor bleedingCoronary syndromeIschemic eventsRandomized trialsComparative efficacyTicagrelorBleedingPatientsSyndromeTrials
2019
A systematic review of randomized trials comparing double versus triple antithrombotic therapy in patients with atrial fibrillation undergoing percutaneous coronary intervention
Sullivan AE, Nanna MG, Rao SV, Cantrell S, Gibson CM, Verheugt FWA, Peterson ED, Lopes RD, Alexander JH, Granger CB, Yee MK, Kong DF. A systematic review of randomized trials comparing double versus triple antithrombotic therapy in patients with atrial fibrillation undergoing percutaneous coronary intervention. Catheterization And Cardiovascular Interventions 2019, 96: e102-e109. PMID: 31713326, PMCID: PMC7211549, DOI: 10.1002/ccd.28535.Peer-Reviewed Original ResearchMeSH KeywordsAcute Coronary SyndromeAgedAnticoagulantsAtrial FibrillationCoronary ThrombosisDual Anti-Platelet TherapyFemaleFibrinolytic AgentsHemorrhageHumansMalePercutaneous Coronary InterventionPlatelet Aggregation InhibitorsPurinergic P2Y Receptor AntagonistsRandomized Controlled Trials as TopicRisk FactorsTreatment OutcomeConceptsPercutaneous coronary interventionAcute coronary syndromeDouble therapyOral anticoagulationAtrial fibrillationTriple therapyAntithrombotic therapyCoronary syndromeCoronary interventionStent thrombosisMajor adverse cardiovascular eventsTriple antithrombotic therapyAdverse cardiovascular eventsDual antiplatelet therapyOptimal antithrombotic therapyGood safety profileRandom-effects modelIschemic outcomesAntiplatelet therapyCardiovascular eventsP2Y12 inhibitorsMedical managementRandomized trialsIntracranial hemorrhageSafety profileAge, knowledge, preferences, and risk tolerance for invasive cardiac care
Nanna MG, Peterson ED, Wu A, Harding T, Galanos AN, Wruck L, Alexander KP. Age, knowledge, preferences, and risk tolerance for invasive cardiac care. American Heart Journal 2019, 219: 99-108. PMID: 31733450, PMCID: PMC6944066, DOI: 10.1016/j.ahj.2019.09.008.Peer-Reviewed Original ResearchConceptsInvasive cardiac careAcute coronary syndromeInvasive cardiovascular proceduresCardiac careCardiovascular proceduresSingle academic medical centerCoronary artery bypassProspective cohort studyPercutaneous coronary interventionGroup of patientsConfidence intervalsSubstantial inter-individual variabilityAcademic medical centerArtery bypassCABG surgeryCoronary syndromeBaseline characteristicsCohort studyCoronary interventionYounger patientsCardiac catheterizationInvasive careInter-individual variabilityCare teamCardiovascular care
2017
Benefits and risks of P2Y12 inhibitor preloading in patients with acute coronary syndrome and stable angina
Bazemore TC, Nanna MG, Rao SV. Benefits and risks of P2Y12 inhibitor preloading in patients with acute coronary syndrome and stable angina. Journal Of Thrombosis And Thrombolysis 2017, 44: 303-315. PMID: 28730406, DOI: 10.1007/s11239-017-1529-6.Peer-Reviewed Original ResearchConceptsAcute coronary syndromeP2Y12 inhibitorsStable anginaCoronary syndromeCardiac catheterizationCoronary artery bypass graft surgeryArtery bypass graft surgeryAdverse ischemic eventsP2Y12 inhibitor administrationP2Y12 inhibitor pretreatmentAdverse cardiovascular eventsBypass graft surgeryPercutaneous coronary interventionStandard of careCardiovascular eventsGraft surgeryCoronary interventionIschemic eventsInhibitor administrationOperative delayPatientsInhibitor pretreatmentAnginaCatheterizationAppropriate timing